Stress BioSciences to Increase on Pivotal Change in Enterprise Technique with Presentation at H. C. Wainwright Annual International Funding Convention on September Thirteenth

0
4
Advertisement

Firm Shifts Major Enterprise Focus to Revolutionary UST Platform. Expects to Enter FY 2023 with

Ten or Extra Tolling Contracts. Believes Every Contract May Generate $1 Million or Extra in PBI Income.

SOUTH EATON, MA / ACCESSWIRE / September 13, 2022 / Stress BioSciences, Inc. (OTCQB:PBIO) (“PBI” and the “Firm”), a pacesetter within the growth and sale of progressive, broadly enabling, pressure-based devices, consumables, and specialty testing companies to the worldwide life sciences, nutraceuticals, cosmetics, meals & beverage, and different key industries, right this moment introduced the Firm’s participation within the September 12-14 H. C. Wainwright Annual International Investor Convention. This convention will function numerous thrilling, rapidly-growing private and non-private corporations, presenting for half-hour every. PBI’s President and CEO, Mr. Richard T. Schumacher, will likely be talking on September 13th at 1:30 pm ET.

Over the previous 4 months, PBI has introduced the execution of three agreements protecting the manufacturing, distribution, industrial roll-out, and monetary partnership for novel, successfully water-soluble, extremely bioavailable, nanoemulsified CBD merchandise for each oral and topical use. Lately, the Firm additionally introduced the execution of a cosmeceuticals partnership with Dr. Denese SkinScience, a 20-year skincare business chief with over $500 million in QVC gross sales.

All 4 contracts are based mostly on the usage of the Firm’s patented, Extremely Shear Expertise™ (UST™) platform to develop nanoemulsions of oil-based nutraceuticals and cosmetics. Nanoemulsions are recognized to show oil-based energetic ingredient mixtures (e.g., CBD, THC, Astaxanthin, Curcumin, Retinol, Prednisone) into long-term steady, successfully water-soluble, extremely bioavailable formulations. The Firm believes these 4 contracts alone might generate over $5 million of accretive income for PBI in 2023. The Firm plans to shut on a minimal of six extra contracts over the remaining months of FY 2022.

DATE: Tuesday, September 13, 2022 (1:30 pm ET)

PRESENTATION: Video Webcast – Presentation plus Q&A

REGISTER: Hyperlink to PBIO Presentation – HCW Investor Conf.

Highlights of PBI’s Latest Press Releases on the Launch of UST-Processed, Nanoemulsified CBD and Cosmeceutical Merchandise – with Estimated Annual 2023 Income to PBI Anticipated to Exceed $5,000,000:

  • PBI has executed three contracts that decision for the Firm to fabricate 1000’s of liters of UST-processed CBD nanoemulsion bulk materials throughout This fall 2022

  • CBD bulk nanoemulsion materials will likely be despatched to the Firm’s contractors who will vial, label, promote, and distribute the fabric by way of their e-commerce websites, sub-distributors, and different established gross sales channels

  • These distinctive merchandise are anticipated to be long-term steady, successfully water-soluble, extremely bioavailable nanoemulsions of CBD for oral and topical use

  • Formulation of the preliminary merchandise has been accomplished: solely plant-based reagents are used within the merchandise

  • Safer Medical of Montana (SMM), Cover CBD Farms (CCF), and North Star Holdings (NSH) will associate with PBI on manufacturing, distribution, industrial roll-out, and monetary returns – phrases of those partnerships are in agreements that had been not too long ago executed by the businesses and PBI

  • These corporations have distribution channels and infrastructure for his or her present well being & wellness merchandise

  • PBI believes first-year gross sales (FY 2023) will meet or exceed $5M in income for PBI

  • PBI believes no different CBD product available on the market can compete with the standard of its UST-processed Nano-CBD

  • PBI has additionally introduced a partnership with Dr. Denese SkinScience to fabricate new and to reinforce present skincare merchandise offered beneath the Dr. Denese label. UST-processed merchandise are anticipated for FY 2023 launch.

About H.C. Wainwright

H.C. Wainwright is a full‐service funding financial institution devoted to offering company finance, strategic advisory, company entry, and associated companies to private and non-private corporations throughout a number of sectors and areas. H.C. Wainwright & Co. additionally gives fairness analysis and gross sales & buying and selling companies to institutional buyers. In response to Placement Tracker, H.C. Wainwright’s group is ranked because the #1 Placement Agent when it comes to combination CMPO (confidentially marketed public providing), RD (registered direct providing) and PIPE (non-public funding in public fairness) executed cumulatively since 1998. For extra data go to H.C. Wainwright & Co. on the Web at www.hcwco.com

About Stress BioSciences, Inc.

Stress BioSciences, Inc. (OTCQB:PBIO) is a pacesetter within the growth and sale of progressive, broadly enabling, pressure-based options for the worldwide life sciences and different industries. Our merchandise are based mostly on the distinctive properties of each fixed (i.e., static) and alternating (i.e., strain biking know-how, or PCT) hydrostatic strain. PCT is a patented enabling know-how platform that makes use of alternating cycles of hydrostatic strain between ambient and ultra-high ranges to manage bio-molecular interactions safely and reproducibly (e.g., cell lysis, biomolecule extraction). Our main focus is the event of PCT-based merchandise for biomarker and goal discovery, drug design and growth, biotherapeutics characterization and high quality management, soil & plant biology, forensics, and counter-bioterror functions. Moreover, main new market alternatives have emerged in the usage of our pressure-based applied sciences within the following areas: (1) the usage of our not too long ago acquired, patented know-how from BaroFold, Inc. (the “BaroFold” know-how) to permit entry into the bio-pharma contract companies sector, and (2) the usage of our recently-patented, scalable, high-efficiency, pressure-based Extremely Shear Expertise (“UST”) platform to (i) create steady nanoemulsions of in any other case immiscible fluids (e.g. oils and water) and to (ii) put together increased high quality, homogenized, prolonged shelf-life or room temperature steady low-acid liquid meals that can’t be successfully preserved utilizing present non-thermal applied sciences.

Ahead Wanting Statements

This press launch accommodates forward-looking statements. These statements relate to future occasions or our future monetary efficiency and contain recognized and unknown dangers, uncertainties and different components that will trigger our or our business’s precise outcomes, ranges of exercise, efficiency, or achievements to be materially totally different from any future outcomes, ranges of exercise, efficiency or achievements expressed, implied, or inferred by these forward-looking statements. In some instances, you possibly can determine forward-looking statements by terminology comparable to “could,” “will,” “ought to,” “might,” “would,” “expects,” “plans,” “intends,” “anticipates,” “believes,” estimates,” “predicts,” “tasks,” “potential” or “proceed” or the unfavorable of such phrases and different comparable terminology. These statements are solely predictions based mostly on our present expectations and projections about future occasions. You shouldn’t place undue reliance on these statements. In evaluating these statements, it is best to particularly think about numerous components. Precise occasions or outcomes could differ materially. These and different components could trigger our precise outcomes to vary materially from any forward-looking assertion. These dangers, uncertainties, and different components embrace, however should not restricted to, the dangers and uncertainties mentioned beneath the heading “Danger Elements” within the Firm’s Annual Report on Type 10-Ok for the 12 months ended December 31, 2021, and different experiences filed by the Firm once in a while with the SEC. The Firm undertakes no obligation to replace any of the data included on this launch, besides as in any other case required by regulation.

For extra details about PBI and this press launch, please click on on the next web site hyperlink:

http://www.pressurebiosciences.com

Please go to us on Fb, LinkedIn, and Twitter.

SOURCE: Stress BioSciences Inc.

View supply model on accesswire.com:
https://www.accesswire.com/715767/Stress-BioSciences-to-Increase-on-Pivotal-Change-in-Enterprise-Technique-with-Presentation-at-H-C-Wainwright-Annual-International-Funding-Convention-on-September-Thirteenth

Advertisement

LEAVE A REPLY

Please enter your comment!
Please enter your name here